Potential Application of Tirzepatide in the Management of Polycystic Ovary Syndrome: A Narrative Review
Potential Application of Tirzepatide in the Management of Polycystic Ovary Syndrome: A Narrative Review
DOI:
https://doi.org/10.51473/rcmos.v1i2.2025.1548Keywords:
Polycystic Ovary Syndrome; Tirzepatide; GLP-1; GIP; obesity; insulin resistance.Abstract
Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders in women of reproductive age, characterized by hormonal dysfunction, insulin resistance, and an increased risk of obesity, type 2 diabetes, and cardiovascular disease. Tirzepatide, a dual GLP-1 and GIP receptor agonist, has demonstrated significant efficacy in glycemic control in patients with type 2 diabetes (FRIAS ET AL., 2021) and induces weight reductions of over 20% in obese patients (JASTREBOFF ET AL., 2022), suggesting its therapeutic potential also in women with PCOS. This paper reviews the current knowledge on the use of tirzepatide in this context, addressing its mechanisms of action, expected metabolic effects, limitations, and evidence gaps. It is concluded that, although promising, tirzepatide lacks specific clinical studies in PCOS, and controlled longitudinal trials are needed to confirm its efficacy and safety in this population (ANALA ET AL., 2023; CHÁVEZ, 2023).
Downloads
References
ANALA, A. D.; SAIFUDEEN, I. J. H.; IBRAHIM, M.; NANDA, M.; NAAZ, N.; ATKIN, S. L. The potential utility of tirzepatide for the management of polycystic ovary syndrome. Journal of Clinical Medicine, v. 12, n. 14, p. 4575, 2023. DOI: 10.3390/jcm12144575. Acesso em: 24 set. 2025. DOI: https://doi.org/10.3390/jcm12144575
HIMELEIN, M. J.; THATCHER, S. S. Síndrome do ovário policístico e saúde mental: uma revisão. Obstetrics and Gynecology Survey, v. 61, p. 723–732, 2006. DOI: 10.1097/01.ogx.0000243772.33357.84. Acesso em: 29 set. 2025. DOI: https://doi.org/10.1097/01.ogx.0000243772.33357.84
TEEDE, H.; DEEKS, A.; MORAN, L. Síndrome dos ovários policísticos: uma condição complexa com manifestações psicológicas, reprodutivas e metabólicas que impacta a saúde ao longo da vida. BMC Medicine, v. 8, p. 41, 2010. DOI: 10.1186/1741-7015-8-41. Acesso em: 30 set. 2025. DOI: https://doi.org/10.1186/1741-7015-8-41
ASHRAF, S.; NABI, M.; RASOOL, S. U. A.; RASHID, F.; AMIN, S. Hiperandrogenismo na síndrome do ovário policístico e papel das variantes do gene CYP: uma revisão. Egyptian Journal of Medical Human Genetics, v. 20, p. 25, 2019. DOI: 10.1186/s43042-019-0031-4. Acesso em: 1 out. 2025. DOI: https://doi.org/10.1186/s43042-019-0031-4
CENA, H.; CHIOVATO, L.; NAPPI, R. E. Obesidade, Síndrome do Ovário Policístico e Infertilidade: Uma Nova Avenida para Agonistas do Receptor GLP-1. Journal of Clinical Endocrinology & Metabolism, v. 105, p. e2695–e2709, 2020. DOI: 10.1210/clinem/dgaa285. Acesso em: 2 out. 2025. DOI: https://doi.org/10.1210/clinem/dgaa285
KNOCHENHAUER, E. S.; KEY, T. J.; KAHSAR-MILLER, M.; WAGGONER, W.; BOOTS, L. R.; AZZIZ, R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. Journal of Clinical Endocrinology & Metabolism, v. 83, n. 9, p. 3078–3082, 1998. Acesso em: 2 out. 2025. DOI: https://doi.org/10.1210/jc.83.9.3078
BARBOSA, M. A. S.; REIS, F. R. DA S.; MARQUEZ, C. O. Atenção farmacêutica no tratamento da obesidade envolvendo os análogos do Glucagon-like Peptide 1 (GLP-1). Research, Society and Development, v. 11, n. 7, 2022. Acesso em: 4 out. 2025. DOI: https://doi.org/10.33448/rsd-v11i7.30134
CHAVDA, V. P.; et al. Tirzepatide, a new era of dual-targeted treatment for diabetes and obesity: a mini-review. Molecules, v. 27, n. 13, 2022. Acesso em: 5 out. 2025. DOI: https://doi.org/10.3390/molecules27134315
CHÁVEZ, M. Tirzepatida: un avance revolucionario en el tratamiento de la diabetes mellitus tipo 2 y la obesidad. Revista Eristas, v. 4, n. 1, 2023. Acesso em: 6 out. 2025. DOI: https://doi.org/10.61616/rvdc.v4i1.39
GRACIA, M. F. M.; et al. Eficacia de la tirzepatida en pacientes con diabetes mellitus tipo 2 y obesidad: un innovador fármaco dual. Ciencia Latina Revista Científica Multidisciplinar, v. 7, n. 1, p. 2370–2082, 2023. Acesso em: 7 out. 2025. DOI: https://doi.org/10.37811/cl_rcm.v7i1.4596
FRIAS, J. P.; DAVIES, M. J.; ROSENSTOCK, J.; et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine, v. 385, p. 503–515, 2021. DOI: 10.1056/NEJMoa2107519. Acesso em: 12 out. 2025. DOI: https://doi.org/10.1056/NEJMoa2107519
JASTREBOFF, A. M.; ARONNE, L. J.; AHMAD, N. N.; et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, v. 387, p. 205–216, 2022. DOI: 10.1056/NEJMoa2206038. Acesso em: 12 out. 2025. DOI: https://doi.org/10.1056/NEJMoa2206038
Downloads
Published
Issue
Section
Categories
License
Copyright (c) 2025 Larissa Assumpção Gimenes de Souza, Allan Douglas Azevedo Brim, Augusto Cesar Carvalho da Silva Filho, Mayra da Silva Freire, Renato Assumpção Gimenes de Souza, Mauricio Cupello Peixoto (Autor)
This work is licensed under a Creative Commons Attribution 4.0 International License.
This work is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This means you are free to:
- Share — copy and redistribute the material in any medium or format.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
The use of this material is conditioned upon proper attribution to the original author(s), providing a link to the license, and indicating if changes were made. The license does not require permission from the author or the publisher as long as these conditions are met.
The Creative Commons license logo is displayed permanently in the footer of the journal.
The copyright of the manuscript can be retained by the authors without restrictions and can be requested at any time, even after publication in the journal.
